Please assess the completion status of the following clinical trial:

Trial Title: ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participant has hemophilia A {FVIII lesser than or equal to (\<=)5%}~* Participant is prescribed Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM) or Antihemophilic Factor (Recombinant) - Pegylated (rAHF-PEG) by the treating physician~* Participant or participant's legally authorized representative provides informed consent~Exclusion Criteria:~* Participant has known hypersensitivity to the active substance or any of the excipients~* Participant has known allergic reaction to mouse or hamster proteins~* Participant has participated in another clinical study involving an investigational product (IP) or device within 30 days prior to study enrollment or is scheduled to participate in another clinical study involving another FVIII concentrate or device during the course of this study

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rAHF-PFM (Type: None): Participants treated with rAHF-PFM alone
- rAHF-PEG (Type: None): Participants treated with rAHF-PEG alone
- rAHF-PFM then rAHF-PEG (Type: None): Participants treated with rAHF-PFM and subsequently switched to rAHF-PEG

Based on this trial design, predict the completion outcome and termination type (if applicable).